Labcorp to Offer HPV and STI Self-Collection Options in Labcorp Patient Service Centers and Participating Physician Offices Nationwide

New offering expands screening options for cervical cancer and sexually transmitted infections (STIs), including chlamydia, gonorrhea, trichomonas or mycoplasma genitalium (Mgen) BURLINGTON, N.C., April 1, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer nationwide a U.S. Food and Drug Administration (FDA) approved human papillomavirus (HPV) self-collection solution that can help women and their physicians asses the r ...